CY1113368T1 - Αλας π-τολουολο σουλφονικου οξεος της 5-αμινο-3-(2'-ο-ακετυλ-3'-δεοξυ-βητα-d-ριβοφουρανοζυλ)-3η-θειαζολο[4,5-d]πυριμιδινο-2-ονης και μεθοδοι παρασκευης - Google Patents

Αλας π-τολουολο σουλφονικου οξεος της 5-αμινο-3-(2'-ο-ακετυλ-3'-δεοξυ-βητα-d-ριβοφουρανοζυλ)-3η-θειαζολο[4,5-d]πυριμιδινο-2-ονης και μεθοδοι παρασκευης

Info

Publication number
CY1113368T1
CY1113368T1 CY20121100897T CY121100897T CY1113368T1 CY 1113368 T1 CY1113368 T1 CY 1113368T1 CY 20121100897 T CY20121100897 T CY 20121100897T CY 121100897 T CY121100897 T CY 121100897T CY 1113368 T1 CY1113368 T1 CY 1113368T1
Authority
CY
Cyprus
Prior art keywords
thiazolo
deoxy
acetyl
beta
amino
Prior art date
Application number
CY20121100897T
Other languages
English (en)
Inventor
David Kucera
Gregory J Haley
Erik J Rueden
Tingman Wang
Martin Viertelhaus
Fritz Blatter
Original Assignee
Anadys Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anadys Pharmaceuticals, Inc. filed Critical Anadys Pharmaceuticals, Inc.
Publication of CY1113368T1 publication Critical patent/CY1113368T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η παρούσα αποκάλυψη αφορά σε άλας π-τολούολο σουλφονικού οξέος της 5-αμινο-3-(2'-O-ακετυλ-3'-δεοξυ-βητα-D-ριβοφουρανοζυλ)-3Η-θειαζολο[4,5-d]πυριμιδιν-2-όνης και χρήση αυτού στη θεραπεία καταστάσεων όπως ιικών μολύνσεων, όγκων και καρκίνων. Επίσης αποκαλυπτόμενη είναι μια μέθοδος παρασκευής του άλατος π-τολούολο σουλφονικού οξέος της 5-αμινο-3-(2'-O-ακετυλ-3'-δεοξυ-βητα-D-ριβοφουρανοζυλ)-3Η-θειαζολο[4,5-d]πυριμιδιν-2-όνης και μέθοδοι για παρασκευή ενώσεων φουρανόζης, οι οποίες είναι χρήσιμα ενδιάμεσα στην παρασκευή φαρμακευτικών ενώσεων, όπως άλατος π-τολούολο σουλφονικού οξέος της 5-αμινο-3-(2'-O-ακετυλ-3'-δεοξυ-βητα-D-ριβοφουρανοζυλ)-3Η-θειαζολο[4,5-d]πυριμιδιν-2-όνης και των παρομοίων.
CY20121100897T 2006-10-17 2012-09-28 Αλας π-τολουολο σουλφονικου οξεος της 5-αμινο-3-(2'-ο-ακετυλ-3'-δεοξυ-βητα-d-ριβοφουρανοζυλ)-3η-θειαζολο[4,5-d]πυριμιδινο-2-ονης και μεθοδοι παρασκευης CY1113368T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85200206P 2006-10-17 2006-10-17
US89940507P 2007-02-05 2007-02-05
US95359707P 2007-08-02 2007-08-02
EP07873546A EP2076132B1 (en) 2006-10-17 2007-10-16 P-toluene sulfonic acid salt of 5-amino-3-(2'-o-acetyl-3'-deoxy-beta -d-ribofuranosyl)-3h-thiazole [4, 5-d]pyrimidine-2-one and methods for preparation

Publications (1)

Publication Number Publication Date
CY1113368T1 true CY1113368T1 (el) 2016-06-22

Family

ID=39472747

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100897T CY1113368T1 (el) 2006-10-17 2012-09-28 Αλας π-τολουολο σουλφονικου οξεος της 5-αμινο-3-(2'-ο-ακετυλ-3'-δεοξυ-βητα-d-ριβοφουρανοζυλ)-3η-θειαζολο[4,5-d]πυριμιδινο-2-ονης και μεθοδοι παρασκευης

Country Status (25)

Country Link
US (2) US7928085B2 (el)
EP (1) EP2076132B1 (el)
JP (2) JP5279715B2 (el)
KR (2) KR101515077B1 (el)
AR (1) AR063484A1 (el)
AU (1) AU2007353381B2 (el)
BR (1) BRPI0717741A2 (el)
CA (2) CA2666537C (el)
CY (1) CY1113368T1 (el)
DK (1) DK2076132T3 (el)
DO (1) DOP2007000131A (el)
EA (1) EA017005B1 (el)
ES (1) ES2390930T3 (el)
HK (1) HK1132429A1 (el)
IL (2) IL198180A (el)
MX (1) MX2009004028A (el)
MY (1) MY150408A (el)
NO (1) NO20091598L (el)
NZ (1) NZ576408A (el)
PE (1) PE20081105A1 (el)
PL (1) PL2076132T3 (el)
PT (1) PT2076132E (el)
TW (1) TWI415854B (el)
UY (1) UY30650A1 (el)
WO (1) WO2008140549A1 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101461604B1 (ko) 2006-06-22 2014-11-18 애나디스 파마슈티칼스, 인코포레이티드 5-아미노-3-(3''-데옥시-β-Ｄ-리보퓨라노실)-티아졸로［4,5-ｄ］파이리미딘-2,7-다이온의 프로드럭
WO2009026292A1 (en) 2007-08-20 2009-02-26 Anadys Pharmaceuticals, Inc. Dosing methods for treating disease
DK3230298T3 (da) 2014-12-08 2021-03-22 Hoffmann La Roche 3-substituerede 5-amino-6H-thiazolo[4,5-d]pyrimidin-2,7-dion forbindelser til behandling og forebyggelse af virusinfektion
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
CA2979490C (en) 2015-03-16 2023-07-18 F. Hoffmann-La Roche Ag Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
JP6779232B2 (ja) 2015-05-08 2020-11-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ウイルス感染の治療又は予防のための新規オキサチオランカルボン酸と誘導体
EP3294746B1 (en) 2015-05-12 2021-10-06 F. Hoffmann-La Roche AG Substituted aminothiazolopyrimidinedione derivatives for the treatment and prophylaxis of virus infection
WO2017001307A1 (en) 2015-06-30 2017-01-05 F. Hoffmann-La Roche Ag Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
EP3568400A1 (en) * 2017-01-06 2019-11-20 H. Hoffnabb-La Roche Ag PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 5-AMINO-6H-THIAZOLO[4,5-d]PYRIMIDINE-2-7-DIONE COMPOUNDS
CN110007010A (zh) * 2018-01-05 2019-07-12 大鹏药品工业株式会社 源自曲氟尿苷的类似物质的检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07224081A (ja) * 1994-02-10 1995-08-22 Kobayashi Koryo Kk デオキシリボフラノシルハライド誘導体の製造方法
US5532374A (en) * 1995-06-06 1996-07-02 Hitachi Chemical Company, Ltd. Method of preparation of bis-quinolines
JP4067226B2 (ja) * 1999-04-01 2008-03-26 三井化学株式会社 １―ハロゲノ−２−デオキシリボフラノース誘導体の製造方法
JP2000327693A (ja) * 1999-05-21 2000-11-28 Mitsui Chemicals Inc ２’−デオキシ−β−シチジン誘導体の製造方法
US6649761B2 (en) * 2001-05-30 2003-11-18 Merck & Co., Inc. Process for preparing piperazinepentaneamide HIV protease inhibitors
CN1300165C (zh) * 2001-11-27 2007-02-14 安那迪斯药品股份有限公司 3－β－呋喃核糖基噻唑并[4,5－d]嘧啶核苷及其应用
WO2004052892A1 (en) * 2002-12-09 2004-06-24 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
AP2006003542A0 (en) * 2003-09-05 2006-04-30 Anadys Pharmaceuticals Inc Administration of TLR7 ligands and prodrugs for treatment of infection by hepatitis C virus.
BRPI0418887A (pt) * 2004-06-07 2007-10-30 Anadys Pharmaceuticals Inc nucleosìdeos de 3-beta-d-ribofuranossiltiazol[4,5-d] pirimidina e usos dos mesmos
JP5303149B2 (ja) * 2004-12-17 2013-10-02 アナディス ファーマシューティカルズ インク ３，５−二置換及び３，５，７−三置換−３Ｈ−オキサゾロ及び３Ｈ−チアゾロ［４，５−ｄ］ピリミジン−２−オン化合物及びそのプロドラッグ
US7501526B2 (en) * 2005-01-20 2009-03-10 Taigen Biotechnology Synthesis of polyamine compounds
KR101461604B1 (ko) 2006-06-22 2014-11-18 애나디스 파마슈티칼스, 인코포레이티드 5-아미노-3-(3''-데옥시-β-Ｄ-리보퓨라노실)-티아졸로［4,5-ｄ］파이리미딘-2,7-다이온의 프로드럭
CN101595117B (zh) * 2006-12-08 2014-01-22 株式会社Api 呋喃糖衍生物的制造方法

Also Published As

Publication number Publication date
HK1132429A1 (el) 2010-02-26
EP2076132B1 (en) 2012-07-11
EP2076132A1 (en) 2009-07-08
TWI415854B (zh) 2013-11-21
PT2076132E (pt) 2012-10-03
IL223126A0 (en) 2012-12-31
CA2666537A1 (en) 2008-11-20
JP5703334B2 (ja) 2015-04-15
IL223126A (en) 2016-08-31
EA017005B1 (ru) 2012-09-28
MX2009004028A (es) 2009-05-11
UY30650A1 (es) 2008-05-31
KR101486444B1 (ko) 2015-01-26
KR101515077B1 (ko) 2015-04-24
EP2076132A4 (en) 2011-05-04
NO20091598L (no) 2009-07-10
DOP2007000131A (es) 2008-09-15
PE20081105A1 (es) 2008-08-15
WO2008140549A1 (en) 2008-11-20
US7928085B2 (en) 2011-04-19
MY150408A (en) 2014-01-15
IL198180A (en) 2015-06-30
KR20140119203A (ko) 2014-10-08
DK2076132T3 (da) 2012-09-10
CA2666537C (en) 2015-12-08
JP2013166782A (ja) 2013-08-29
JP5279715B2 (ja) 2013-09-04
KR20090074237A (ko) 2009-07-06
AU2007353381A1 (en) 2008-11-20
JP2010506947A (ja) 2010-03-04
TW200833699A (en) 2008-08-16
US20090197826A1 (en) 2009-08-06
CA2898225A1 (en) 2008-11-20
NZ576408A (en) 2012-04-27
IL198180A0 (en) 2009-12-24
AR063484A1 (es) 2009-01-28
AU2007353381B2 (en) 2013-07-04
ES2390930T3 (es) 2012-11-19
US20110172447A1 (en) 2011-07-14
US8193342B2 (en) 2012-06-05
PL2076132T3 (pl) 2013-01-31
EA200970387A1 (ru) 2009-10-30
BRPI0717741A2 (pt) 2014-04-08

Similar Documents

Publication Publication Date Title
CY1113368T1 (el) Αλας π-τολουολο σουλφονικου οξεος της 5-αμινο-3-(2'-ο-ακετυλ-3'-δεοξυ-βητα-d-ριβοφουρανοζυλ)-3η-θειαζολο[4,5-d]πυριμιδινο-2-ονης και μεθοδοι παρασκευης
CY1113323T1 (el) Ενωσεις τετραϋδροφουρο[3,4-d]διοξολανιου για χρηση στη θεραπεια ιικων μολυνσεων και καρκινου
CY1121202T1 (el) ΠΑΡΑΓΩΓΑ ΠΥΡΡΟΛΟ[2,3-b)]ΠΥΡΙΜΙΔΙΝΗΣ ΩΣ ΑΝΑΣΤΟΛΕΑΣ ΚΙΝΑΣΗΣ JANUS
CY1123817T1 (el) Μεθοδος για την παρασκευη ενωσεων που ειναι χρησιμες ως αναστολεις sglt
CY1113324T1 (el) Υποκατεστημενα αμιδικα παραγωγα ως αναστολεις πρωτεϊνικων κινασων
CY1119056T1 (el) Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna
CY1116929T1 (el) Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις πρωτεϊνικης κινασης β
CY1119381T1 (el) Παραγωγα 2-μεθυλομορφολινο πυριδο-, πυραζο- και πυριμιδο-πυριμιδινης ως αναστολεις mtor
EA200701808A1 (ru) Производные тетрагидроиндолона и тетрагидроиндазолона
CY1114708T1 (el) Παραγωγα πυραζολο-κιναζολινης, διαδικασια για την παρασκευη τους και η χρηση τους ως αναστολεων κινασης
CY1106207T1 (el) Αντιιικα παραγωγα νουκλεοζιτων
CY1108186T1 (el) Παραγωγα κουιναζολινης ως αναστολεις της κινασης τυροσινης
CY1117319T1 (el) Τρικυκλικα παραγωγα αμινης ως αναστολεις πρωτεϊνικης τυροσινης κινασης
CY1113647T1 (el) Αναλογα καρβα-νουκλεοσιδιου για αντι-ιικη θεραπεια
CY1110914T1 (el) Δικυκλο-πυραζολες δραστικες ως αναστολεις kinασων, διεργασια για την παρασκευη τους και φαρμακευτικες συνθεσεις που τις περιλαμβανουν
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
CY1108415T1 (el) Παραγωγα 4-αμινοπιπεριδινης και η χρησιμοποιηση αυτων ως φαρμακων
CY1113354T1 (el) Αναστολεις φωσφορυλασων και νουκλεοζιδασων νουκλεοζιδιου
PT1404347E (pt) Nucleosidos 4'-substituidos para o tratamento de doencas mediadas pelo virus da hepatite c
CY1113538T1 (el) Παραγωγα της 5-αμινο-2,4,7-τριοξο-3,4,7,8-τετραϋδρο-2η-πυριδο[2,3-d] πυριμιδινης και παρομοιες ενωσεις για την αγωγη του καρκινου
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
CY1109722T1 (el) Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole
EA200200249A1 (ru) Производные 3(5)-уреидопиразола, способ их получения и их применение в качестве противоопухолевых агентов
EA200802203A1 (ru) Дикетопиперазиновые и пиперидиновые производные в качестве противовирусных агентов
CY1111747T1 (el) 8-αζαδικυκλο[3.2.1]οκτανο ενωσεις ως ανταγωνιστες μ-οπιοειδους υποδοχεα